REG - Futura Medical PLC - Posting of Circular and Notice of GM

Futura MedicalAnnouncement

Thu 16:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251113:nRSM4910Ha&default-theme=true

RNS Number : 4910H  Futura Medical PLC  13 November 2025

13 November 2025

Futura Medical plc

("Futura", "the Group" or the "Company")

Posting of Circular and Notice of General Meeting

 

Futura Medical plc (AIM: FUM), the consumer healthcare Group behind Eroxon®,
that specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, announces that
further to the announcement on 13 November 2025 relating to its fundraise of
£2.75 million, it has despatched the Circular and Notice of General Meeting
to Shareholders.

 

The Circular and Notice of General Meeting is available on the Company's
website: Corporate documentation - Futura Medical
(https://futuramedical.com/investor-centre/corporate-documentation/)

 

The Directors confirm they are to hold a General Meeting of the Company at the
Company's registered office at Surrey Technology Centre, 40 Occam Road,
Guildford, Surrey, GU2 7YG at 10 a.m. on 2 December 2025.

 

The results of voting on all resolutions at the General Meeting will be
announced via RNS, and the full results of the voting will be published on the
Company's website after the conclusion of the General Meeting.

 

Contacts:

 Futura Medical plc                          Alex Duggan                       investor.relations@futuramedical.com

                                 (mailto:Investor.relations@futuramedical.com)
                                             Interim Chief Executive Officer

                                 +44 (0)1483 685 670
                                             Angela Hildreth

                                 www.futuramedical.com (http://www.futuramedical.com/)
                                             Finance Director and COO

 Panmure Liberum                             Emma Earl, Will Goode,            +44 (0)20 3100 2000

 Nominated Adviser                           Mark Rogers (Corporate Finance)

 and Broker

 Turner Pope Investments (TPI) Ltd - Broker  James Pope, Andrew Thacker        +44 (0) 20 3657 0050

 Alma Strategic Communications               Rebecca Sanders-Hewett            +44 (0)20 3405 0205

                                             Sam Modlin                        futura@almastrategic.com

                                             Emma Thompson

 

Notes to Editors:

 

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon(®) and products WSD4000 and
Eroxon(®) Intense. Our core strength lies in our research, development and
commercialisation of topically delivered gel formulations in sexual health
products.

 

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5
men globally across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
Around 60% of women experience at least one symptom of sexual dysfunction, and
only one in four women seek professional help, and remain chronically
underserved.

 

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of Erectile Dysfunction ("ED"). The highly differentiated
product, which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten minutes, addresses significant
unmet needs in the ED market. Eroxon(®) has been nominated for a number of
healthcare industry awards and has won two to-date.

 

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe.

 

WSD4000 is a topical treatment designed for the symptoms of impaired sexual
response and function in women. There is currently no regulatory approved OTC
treatment available for impaired sexual response and function in women.
WSD4000 has the potential to be an effective, breakthrough treatment for the
common symptoms associated with impaired sexual response and function, such as
lack of desire, arousal and lubrication.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGFLFVRLVLVLIE



            Copyright 2019 Regulatory News Service, all rights reserved